证券代码：002030 证券简称：达安基因 公告编号：2025-061 广州达安基因股份有限公司 2025 年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 2、本次股东会未涉及变更前次股东会决议。 3、本次股东会以现场投票与网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 5、会议主持人：公司董事长韦典含女士 6、会议召开的合法、合规性：本次股东会的召开符合《公司法》《深圳证券 交易所股票上市规则》（2025 年修订）等有关法律、行政法规、部门规章、规范 1 性文件和《公司章程》的有关规定。 （二）会议出席情况 本次股东会采取现场投票与网络投票相结合的方式进行投票表决。出席本次 股东会的股东及股东授权委托代表 601 人，代表股份 459,359,691 股，占上市公 司总股份的 32.7308％。其中： （1）现场会议召开时间：2025 年 11 月 17 日下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间 ...

7. 公司本次股东会议案及涉及相关议案内容的公告等文件； 北京市金杜（广州）律师事务所 关于广州达安基因股份有限公司 2025 年第四次临时股东会的法律意见书 致：广州达安基因股份有限公司 北京市金杜（广州）律师事务所（以下简称本所）接受广州达安基因股份有 限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证 券法》）、《中华人民共和国公司法》（以下简称《公司法》）、《上市公司股东会规 则》（以下简称《股东会规则》）等中华人民共和国境内（以下简称中国境内，为 本法律意见书之目的，不包括中国香港特别行政区、中国澳门特别行政区和中国 台湾省）现行有效的法律、行政法规、规章和规范性文件和现行有效的《广州达 安基因股份有限公司公司章程》（以下简称《公司章程》）有关规定，指派律师出 席了公司于 2025 年 11 月 17 日召开的 2025 年第四次临时股东会（以下简称本 次股东会），并就本次股东会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2025 年第三次临时股东会审议通过的《公司章程》； 2. 公司 2025 年 10 月 3 ...

达安基因公告，2025年11月15日，广州金控集团、广州健康产投与广药集团签署了《关于广州达安基因 股份有限公司控股权收购框架协议》。广药集团拟受让广州金控集团持有的广永科技100%股权，从而 间接控制广永科技持有的达安基因2.33亿股股份，并另行通过协议转让方式受让广州金控集团持有的达 安基因7017.23万股股份和广州健康产投持有的达安基因7017.23万股股份。若交易实施完成，广药集团 将合计控制公司3.74亿股股份，占公司总股本的26.63%，成为公司的间接控股股东。 ...

Core Insights - The medical testing industry is facing significant challenges due to increased accounts receivable and declining profits, particularly following the COVID-19 pandemic [1][4][5] Group 1: Accounts Receivable and Financial Performance - Four companies have accounts receivable exceeding 2 billion yuan, with Capbio (凯普生物) involved in lawsuits to recover 357 million yuan in overdue payments [1] - In the first three quarters of this year, at least seven medical testing companies reported net losses attributable to shareholders, with six of them expected to continue this trend into 2024 [1] - Specific losses reported include: Puni Testing (谱尼测试) at 199 million yuan, RunDa Medical (润达医疗) at 163 million yuan, and Capbio at 128 million yuan [1] Group 2: Impact of Price Reductions and Impairment Provisions - Price reductions in the testing sector have led to widespread profit shrinkage among medical testing companies, with some firms making impairment provisions for accounts receivable [4] - Companies like KingMed Diagnostics (金域医学) have made significant impairment provisions, totaling 345 million yuan, primarily for accounts receivable, which reduced their consolidated profit by the same amount [4] - Lanwei Medical (兰卫医学) reported a total impairment provision of 16.73 million yuan, with 13.50 million yuan specifically for accounts receivable [5] Group 3: Recovery Trends and Future Outlook - The Ministry of Finance has indicated a commitment to debt reduction policies, which may accelerate the collection of accounts receivable from public hospitals [5] - Companies are implementing strategies to manage accounts receivable more effectively, with Puni Testing focusing on tailored collection strategies for major clients [6] - DiAn Diagnostics (迪安诊断) anticipates improved collection trends in the second half of the year, with expectations that all COVID-related accounts receivable will be fully provisioned by year-end [5][6]

证券日报网讯达安基因（002030）11月13日在互动平台回答投资者提问时表示，公司仅提供每月月末股 东人数，截至2025年10月31日，公司股东总户数约为13万9千户。 ...

格隆汇11月10日丨达安基因(002030.SZ)在投资者互动平台表示，公司开发有针对甲型、乙型流感病毒 的检测试剂产品，可以适配甲、乙流常规分型的病毒检测需求。公司会持续跟踪流感病毒变异情况，以 获取最新检测需求动态。 ...

Group 1 - The company has developed testing reagents for both influenza A and B viruses, catering to the routine classification needs for these viruses [1] - The company will continuously monitor the mutation of influenza viruses to stay updated on the latest testing demand dynamics [1]

Core Viewpoint - The company, Da'an Gene, stated that as of October 31, 2025, the total number of shareholders is expected to be approximately 139,000 [2] Summary by Relevant Sections - Shareholder Information - The company anticipates having around 139,000 shareholders by the end of October 2025 [2]

Market Overview - The precision medicine sector experienced a decline of 1.77% on November 4, with TuoJing Life leading the drop [1][2] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable stock performances in the precision medicine sector included: - RenDu Bio (688193) closed at 52.90, up 1.05% with a trading volume of 7076.23 hands and a transaction value exceeding 36.99 million yuan [1] - TuoJing Life (300642) closed at 22.73, down 2.86% with a trading volume of 78,200 hands and a transaction value of 178 million yuan [2] - Other companies like DaAn Gene (002030) and Anke Bio (300009) showed minimal changes, with DaAn Gene remaining flat at 6.57 and Anke Bio down 0.55% to 10.84 [1][2] Capital Flow - The precision medicine sector saw a net outflow of 979 million yuan from institutional investors, while retail investors contributed a net inflow of 642 million yuan [2][3] - Specific stock capital flows indicated: - GuoMai Technology (002093) had a net inflow of 8.61 million yuan from institutional investors, while retail investors saw a net outflow of 15.98 million yuan [3] - TuoJing Life experienced minimal net inflow from institutional investors at 25,000 yuan, with retail investors also showing a slight outflow [3]

Core Insights - The company, Da'an Gene, focuses on PCR diagnostic reagents and related consumables and instruments [1] - The integration of AI technology aims to enhance the efficiency of pathogen detection based on high-throughput sequencing [1] - AI will also support data processing and report interpretation, improving accuracy and efficiency in report analysis [1]